You are here: Industry Insights > CAR-T

News List

Novartis changes NICE's mind on Kymriah, giving CAR-T rival Gilead some company fiercepharma
February 01, 2019
Payer coverage is key to Novartis’ plan to get Kymriah going, and the company is going to be getting some more of that.
Lilly’s CEO looks to M&A, but not for CAR-T or gene therapies pharmaphorum
January 15, 2019
Eli Lilly’s CEO David Ricks could sign more deals to strengthen its pipeline of cancer drugs, but is leaving gene cell-based CAR-T oncology drugs and rare disease gene therapies for others to develop......
Lilly eyes more cancer deals, but wary of CAR-T, gene therapy firstwordpharma
January 13, 2019
Eli Lilly CEO Dave Ricks said that as the company looks for deals to enhance its pipeline of future treatments it will leave CAR-T therapies for cancer and gene therapy for rare diseases to others, as reported Yahoo Finance Friday.
Takeda announces multiple cell therapy collaborations biospectrumasia
January 04, 2019
New collaborations expand Takeda’s commitment to pursue the discovery of novel cell therapy approaches to treat blood cancers and solid tumors.
ASH18: Bluebird’s anti-BCMA has a ‘clear lead’ in a crowded field fiercebiotech
January 02, 2019
This year’s ASH saw a plethora of presentations on BCMA-targeting drugs, but analysts at Jefferies say Bluebird Bio’s CAR-T therapy bb2121 “is still leading the pack.”....
Novartis, still struggling with Kymriah manufacturing, is providing some out-of-spec doses to patients who ask fiercepharma
December 26, 2018
Novartis released some new data on CAR-T drug Kymriah this month that it hopes will improve the uptake of the drug. But Novartis also continues to wrestle with manufacturing issues that have kept some doses
Bellicum reports first data on ‘controllable’ CAR-T fiercebiotech
December 26, 2018
Bellicum Pharma has the first data on BPX-601, its first CAR-T with a built-in activation switch to boost its effects, and says initial results show signs of biologic activity.....
Merck KGaA hands over CAR-T therapy business to Intrexon in deal worth $175 million pharmafile
December 24, 2018
German pharma firm Merck KGaA has agreed to hand over its CAR-T therapy business to US company Intrexon in a deal worth $175 million.
Merck takes a back seat on CAR-T, handing assets to Intrexon pharmaphorum
December 24, 2018
Merck KGaA wants to get bigger in immuno-oncology, but from now on it won’t be taking a direct role in the drive to develop new CAR-T therapies.
Novartis, still struggling with Kymriah manufacturing, is providing some out-of-spec doses to patients who ask fiercepharma
December 19, 2018
Novartis released some new data on CAR-T drug Kymriah this month that it hopes will improve the uptake of the drug. But Novartis also continues to wrestle with manufacturing issues that have kept some doses from meeting specifications, a problem that is a

Previous page 1 2 3 4 5 6 7 8 9 10 ... 13 14 Next page